North America Diabetes Care Devices Market By Product Type (Blood Glucose Monitoring Devices {Continuous Glucose Monitoring Systems and Self-Monitoring Blood Glucose Systems} and Treatment Devices {Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, and Others}), By Technology (Wearable Devices and Non-Wearable Devices), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Stores), and By End-User (Hospitals and Clinics, Ambulatory Surgical Centers, and Home Care), Regional Market Size, Segmental analysis, Country Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The North America Diabetes Care Devices market accounted for USD 13.58 Billion in 2024 and is expected to reach USD 35.75 Billion by 2035, growing at a CAGR of around 9.2% between 2025 and 2035. The North America Diabetes Care Devices Market comprises blood glucose meters, insulin delivery systems, continuous glucose monitoring (CGM) systems, and diabetes management applications. These specific markets exist due to the growing incidence of diabetes as a result of factors like a high obesity index, reduced physical activity, and an aging population. Mobile/non-invasive smart insulin pens and advanced integrated diabetes management systems are increasing the value and utility of diabetes care for patients. Competitors in the market for diabetes treatment, both type 1 and type 2, are composed of established companies and emerging startups. Furthermore, growing awareness and understanding of diabetes care are fueling market expansion.

Report Scope:

Market Dynamics

Increasing diabetes cases from lifestyle changes and aging populations.

The North American diabetes care devices market is driven by the prevalence of Diabetes attributed to deteriorating lifestyles, increasing obesity levels, and an aging population. Trends toward obesity are rising, and as individuals live longer, more of them suffer from diabetes and require improved diabetic management. Moreover, due to technological progress, diabetes care devices have become complex and innovative, such as CGM and insulin delivery systems, which help patients improve their adherence levels. A fact revealing the importance of efficient care solutions is that, as of 2020, around 37.3 million people in the United States had diabetes, the Centers for Disease Control and Prevention (CDC) reported. The rising rate of diabetes, along with the increasing adoption of personalized medicine, is expected to drive further expansion in the diabetic care device market in the coming years.

Demand for user-friendly devices improves treatment adherence and engagement.

The rising incidence of diabetes is the main driver for the North America market for diabetes care devices. The growing population and elderly age, high healthcare spending, and the benefits of technological advancements are contributing factors. More amiable devices are needed for better adherence and engagement to treatment. Innovations in continuous glucose monitoring (CGM) systems, insulin pumps, and glucometers are further improving the convenience and effectiveness of diabetes management.

Advancements in mobile applications and cloud-based platforms are further improving patient monitoring and the scope of personalized care. All these factors and increased awareness of government initiatives and technological innovations contribute to the growth of the North America diabetes care devices market. Moreover, the demand for diabetes care devices emphasizes remote patient monitoring and the growing adoption of telehealth services. As healthcare providers and patients seek more convenient and accessible ways to manage diabetes, user-friendly devices that enable effective self-management will play a major role in improving patient outcomes.

Inconsistent insurance coverage hinders device adoption and utilization.

Various insurance policies and changes in coverage put patients' out-of-pocket expenses for equipment like insulin pumps and continuous glucose monitors in doubt. These are a few constraints faced by the North America diabetes care devices market. The inconsistency in insurance coverage is causing discouragement among users to invest in these technologies, especially for those with limited financial resources. Further, the introduction of novel and inventive products may be delayed by long approval processes and regulatory challenges, decreasing customer choice.

Concerns over data protection and security will also cause some patients to shun connected devices. Lack of understanding between the health providers and the patient regarding the benefits and functionalities of such devices will further slow the market growth. These factors put together are barriers to fuller adoption and integration of diabetes care technologies into daily care.

Technology and healthcare collaborations can enhance product offerings.

The opportunities for growth in the North America Diabetes Care Devices Market lie in technological development or collaboratively working with the healthcare industry. Because the disorder is becoming more widespread, the need for novel approaches to improve the effectiveness of patients’ treatment is growing. It is possible to form a society with technology vendors and healthcare organizations to develop new forms of glucose meters, like CGM, that imply real-time analysis based on machine learning algorithms. Furthermore, the usefulness of mobile health applications might be enhanced when these devices are incorporated into the general care plans of patients. The change towards telehealth presents a likelihood of constant supervision and may make diabetes manageable.

Personalized solutions from genetics and data analytics advancements

The North America Diabetes Care Devices Market is at a crossroads, and personalized solutions are now being developed from genetics and big data. Using genetic data, the physicians establish specific strategies for diabetes treatment regarding its metabolic effects and side effects on every patient’s body. This approach may enhance intervention in a personalized manner and relieve the burden of diabetes on patients and patients’ quality of life. However, data analytics makes it possible to monitor patients’ data and make necessary changes in treatment since all information is presented in real-time. Technological advancement, including the incorporation of AI and machine learning into diabetes care devices, improves their capacity to forecast patient requirements. The growing trend of patient-centricity has created consumer-driven value in the market for stakeholders, such as device makers, healthcare entities, and technology firms.

Industry Experts Opinion

“Today more than 500 million people have diabetes, an autoimmune disease that causes the pancreas to produce little or no insulin, leaving sufferers unable to regulate the glucose in their bodies and bloodstreams.”

• Robert B Ford is the Chairman and CEO of Abbott Laboratories.

“The increasing prevalence of diabetes is a public health crisis that requires urgent attention. Advances in treatment and technology, like CGMs and hybrid insulin delivery systems, are game-changers. However, we must focus on ensuring these innovations are accessible to all patients, regardless of their socioeconomic status."

• Dr. John Parker, MD is a board-certified Endocrinologist (Diabetes & Hormones Specialist) in Wilmington, NC

Segment Analysis

Based on the product type, the North America Diabetes Care Devices market is classified into Blood Glucose Monitoring Devices and Treatment Devices. The Blood Glucose Monitoring Devices are considered the largest segment within the North American Diabetes Care Devices Market. This is important because individuals are looking for improved self-management tools as a result of the prevalence of diabetes, especially type 2.

There are new technologies, including continuous glucose monitoring systems that update patients on blood sugar levels to enhance accuracy. Since the test can be taken at home, it makes disease control effective, which is valued more by patients and medical staff. The increasing demand for patient education and responsibilities has boosted the usage of devices. These patterns support the market domination of BGMs and underscore the significance of these devices in improving patient outcomes.

Based on the technology, the North America Pacific Diabetes Care Devices market is classified into Wearable Devices and Non-Wearable Devices. Wearable Devices are the dominant segment in North America Diabetes Care Devices Market. The usage of CGMs and smart pens allows the user to monitor blood sugar levels and the appropriate amount of insulin to take.

Wearables have great potential for improving patient self-governance and anticipating diabetic management due to their reliable data stream. The integration of glucose smartphones and an increase in the precision of the sensor have boosted the use of glucose meters. For this reason, wearable devices help improve the lives of diabetic patients while helping to bring improved performance, making them a leading force in the market.

Regional Analysis

The North America diabetes care devices market distribution is fragmented, with the United States holding the largest and most advanced market. Some drivers that see the growth include the prevalence of diabetes, a change in awareness regarding health, and innovation. Markets with high rates of diabetes are picked out and focused in big cities, including insulin pumps, continuous glucose monitoring (CGM), and smart pen devices. Moreover, the advancement of digital health solutions and the attendance of telemedicine have expanded care. It is important too that regulation policies, reimbursement aspects, and a shifting focus on individualized therapy. Altogether, the more focused opportunity is oriented toward patients and technologies in the United States market.

The North America diabetes care device market is growing in Canada due to the highly spirited demand for novel technologies and focused patient-centric solutions. Because of the prevalence of diabetes in society, this industry is seeing significant advancements in CGMs, insulin delivery systems, and glucose monitoring systems. Hearing improvement in diabetes management through government activities and rising patient awareness levels boosts market growth.

Further, the development of telemedicine and other applications of digital health have improved patient engagement with active models of diabetes management. Such partnerships between healthcare entities and technology firms are designing cooperating solutions for enhancing the quality of patient care. Canada has shown great willingness to healthcare innovation, therefore being determined as a leading market for diabetes care devices.

Competitive Landscape

There is high competition in the North American Diabetes Care Devices Market, such as Dexcom, Insulet Corporation, and Ascensia Diabetes Care, through innovation and strategic partnerships. Dexcom has recently introduced the G7 continuous glucose monitoring system, which is smaller and more accurate. The OmiPod 5 insulin system was cleared by the FDA and connected with a smartphone, making diabetes management even easier with automated insulin delivery. Ascensia Diabetes Care has embraced digital health and launched CONTOUR Diabetes, which offers data analytical statistics. The market is experiencing higher R&D investment and collaborations to localize its products and services to improve patient involvement in diabetes management. Such an environment has been projected to further fuel the improvement of diabetes care, opening up a better future for patients.

North America Diabetes Care Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In July 2024, Fitterfly Healthtech announced a partnership with Ascensia Diabetes Care to improve diabetes management through integrated digital health solutions. This collaboration will merge Fitterfly's personalized health programs with Ascensia's advanced monitoring technologies, aiming to empower patients with comprehensive tools for better glucose control and overall health management.
• In April 2023, The U.S. Food and Drug Administration (FDA) approved Abbott's FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system. There is a reader in this system that is authorized to be used independently. Interestingly, this device makes use of the world's smallest, thinnest, and most covert glucose sensor. Abbott's current priority is to move quickly to add the FreeStyle Libre 3 system to Medicare's list of approved systems.

Report Coverage:

By Product Type

• Blood Glucose Monitoring Devices        
  • Continuous Glucose Monitoring Systems 
  • Self-Monitoring Blood Glucose Systems 
• Treatment Devices
  • Insulin Pens
  • Insulin Pumps 
  • Insulin Jet Injectors
  • Insulin Syringes 
  • Others  

By Technology

• Wearable Devices
• Non-Wearable Devices

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores

By End-User

• Hospitals and Clinics  
• Ambulatory Surgical Centers
• Home Care

By Region

North America

• U.S.
• Canada

List of Companies:

• Dexcom
• Insulet Corporation
• Acon Laboratories
• Frio
• Ascensia Diabetes Care
• GlucoMe
• Zynex Medical
• GlucoGuard
• Glytec
• Bionime
• VivaLNK
• Roche Diabetes Care
• DarioHealth
• WaveForm Technologies
• Genteel

Frequently Asked Questions (FAQs)

---

Related Report